

A' 49. (New) A therapeutic composition useful in treating humans with *Moraxella catarrhalis* comprising at least one antibody directed against the polypeptide of claim 27 and a suitable pharmaceutical carrier.

REMARKS

Claims 1-26 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims as originally filed, and any other claims supported by the specification.

New claims 27-48 have been introduced. No new matter is added.

The status of the claims is as follows:

Amended:	None
Cancelled:	1-26
New:	27-49
Pending:	27-49

The claim fee status is as follows:

- ☒ Large
Entity
☐ Small
Entity


		After Amdmt	Paid for at least	Fee due for	Fee code
	Independent Claims:	3	3	0	Lg =102 Sm =202
	Total Claims	23	20	3	Lg =103 Sm =203

Support for the new claims is either apparent, or is as described in the text below. Support for compositions of the isolated polypeptide which include an adjuvant recited in the claims may be found, for example, at page 44, lines 12-17. Support for the hybridization conditions may be found, for example, at page 14, lines 22-26. Support for the recitation of sequence relatedness such as in claim 37 may be found in the specification, for example, at page 47, line 21 through page 49, line 10. No new matter is added.

Closing Remarks

Prompt examination of the application is earnestly requested.

Respectfully submitted,



Arthur E. Jackson
Registration No. 34,354

DECHERT
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Allen Bloom (609) 620-3214
Arthur E. Jackson (609) 620-3254
Fax: (609) 620-3259
Attn: Allen Bloom, Esq.
(609) 620-3214